Newsroom 2006
Attention Business/Financial Editors:
Neurochem to report on second quarter 2006 - Neurochem will host a conference call Wednesday, Aug. 9, 2006, at 5:00 P.M. ET
LAVAL, QC, Aug. 9 /CNW Telbec/ - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM)
announces that it will release its results for the second quarter of fiscal
2006, today, after the close of market.
The release of the results will be followed by a company-hosted
conference call at 5:00 P.M. Eastern Time, Wednesday, Aug. 9, 2006. During the
conference call, Dr. Francesco Bellini, Chairman, President and Chief
Executive Officer, and Mr. Mariano Rodriguez, Vice President, Finance and
Chief Financial Officer, will present the status and progress of the company,
together with the highlights of its financial results.
To participate in the conference call, please dial the following numbers
approximately 10 minutes prior to the start of the call: 416-644-3416 or
1-866-250-4877. A replay of the conference call will be available for one week
(until Aug. 17, 2006), commencing one hour after the end of the call. The
instant replay numbers are 416-640-1917 or 1-877-289-8525, passcode
21199732 number sign). Please mention that you are calling for the Neurochem
conference replay.
About Neurochem
Neurochem is focused on the development and commercialization of
innovative therapeutics to address critical unmet medical needs. Eprodisate
(Fibrillex(TM)) is designated as an orphan drug, is a Fast Track product
candidate and is also part of FDA Continuous Marketing Application Pilot 1 and
Pilot 2 programs. In April 2006, the FDA confirmed the filing and awarded
Priority review to a New Drug Application for eprodisate (Fibrillex(TM)).
Tramiprosate (Alzhemed(TM)), for the treatment of Alzheimer's disease, is
currently in Phase III clinical trials in both North America and Europe, and
tramiprosate (Cerebril(TM)), for the prevention of Hemorrhagic Stroke caused
by Cerebral Amyloid Angiopathy, has completed a Phase IIa clinical trial.
To Contact Neurochem
For additional information on Neurochem and its drug development
programs, please call the North American toll-free number 1-877-680-4500 or
visit our Web Site at www.neurochem.com.
Certain statements contained in this news release, other than statements
of fact that are independently verifiable at the date hereof, may constitute
forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and
uncertainties, known and unknown, many of which are beyond Neurochem's
control. Such risks include but are not limited to: the impact of general
economic conditions, general conditions in the pharmaceutical industry,
changes in the regulatory environment in the jurisdictions in which Neurochem
does business, stock market volatility, fluctuations in costs, and changes to
the competitive environment due to consolidation, as well as other risks
disclosed in public filings of Neurochem. Consequently, actual future results
may differ materially from the anticipated results expressed in the
forward-looking statements. The reader should not place undue reliance, if
any, on the forward-looking statements included in this news release. These
statements speak only as of the date made and Neurochem is under no obligation
and disavows any intention to update or revise such statements as a result of
any event, circumstances or otherwise. Please see the Annual Information Form
for further risk factors that might affect the Company and its business.
For further information: Lise Hébert, Ph.D. Vice President, Corporate
Communications, (450) 680-4570, lhebert@neurochem.com
